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Abstract
The role of resident microglial cells in the pathogenesis and progression of glial tumors is still obscure mainly due
to a lack of specific markers. Recently P2RY12, a P2 purinergic receptor, was introduced as a specific marker for microglial
cells under normal and pathologic conditions. Here we analyzed the expression of P2RY12 in astrocytomas of various
malignancy grades in relation to markers for M1 and M2 macrophage activation profiles by using two web-based glioma
datasets and confocal immunohistochemistry to 28 astrocytoma samples grades II-IV. In the gliomas, P2RY12
immunoreactivity delineated CD68 negative cells with otherwise microglial features from CD68 positive tumor
associated macrophages (TAMs). The presence of P2RY12 positive cells correlated positively with overall survival. P2RY12
mRNA levels and membrane-bound localization of P2RY12 were inversely correlated with increasing malignancy grade,
and the expression site of P2RY12 shifted from cytoplasmic in low-grade gliomas, to nuclear in high-grade tumors. The
cytoplasmic expression of P2RY12 was associated with the expression of M1 markers, characteristic of the
pro-inflammatory macrophage response. In contrast, the nuclear localization of P2RY12 was predominant in
the higher graded tumors and associated with the expression of the M2 marker CD163.
We conclude that P2RY12 is a specific marker for resident microglia in glioma and its expression and
localization correspond to tumor grade and predominant stage of M1/M2 immune response.
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Introduction
Microglial cells are brain-specific tissue resident macro-
phages that are directly derived from yolk-sac erythromye-
loid precursor cells (EMP) during embryonic development
[19]. As major contributors to the immune status of the
central nervous system (CNS) microglial cells scan the
CNS for cellular debris by continuously protract and retract
their cell processes [26]. The microglial survey mediates the
immune response, supports the homeostasis of the neurons
and, in collaboration with astrocytes, maintains the integrity
of the blood-brain barrier (BBB) [23, 32, 37]. Microglial
cells become activated by a large variety of pathogenic
situations. Upon activation, the cells take on an amoeboid
shape and initiate the paracrine recruitment of blood-
derived macrophages into the altered brain parenchyma,
initiating an inflammatory response [2, 11]. Microglia
serves additional, only partly known, roles in repair pro-
cesses following the acute stage of tissue damage [18, 27].
Recent studies addressing the phenotypic adaptations of
peripheral macrophages in cancer have shown that tumor
associated macrophages (TAMs), similar to the M1 and M2
activation states of macrophages, display particular marker
profiles of pro- and anti-oncogenic action [25, 31]. TAMs
with anti-tumor action share characteristics with M1 mac-
rophages; are capable of antigen presentation and paracrine
signaling to promote inflammation, thereby hampering
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tumor growth and prolonging patient survival [28, 39].
These cells are referred to as M1-like cells. In contrast,
TAMs that promote tumor progression are associated with
an immunosuppressive response; contribute to tumor
angiogenesis and proliferation, and are associated with poor
clinical outcomes [10, 17, 33] and these cells are referred to
as M2-like cells. In general, TAMs are more similar to M2 -
than M1 macrophages [36].
Recent reports have pointed to the heterogeneity of
microglial cells [10]. In glioblastoma, microglia displays a
pro-oncogenic phenotype resembling that of M2-like mac-
rophages, because the cells are in a microenvironment rich
in glioma (stem) cell derived factors like TGF-β1, MCP-1,
PGE-2, and soluble colony stimulating factors [22]. There
is data showing that resident microglia in glioblastomas
plays a role in tumor progression and invasion by the
Table 1 summary of the patients used for immunohistochemistry
Astrocytoma grade II (All) Anaplastic astrocytoma (AA) Glioblastoma (GBM) Control (autopsy brains)
Mean age ± st. dev. 42 ± 12.8 40 ± 12.8 45 ± 14.9 58 ± 13.3
Male/Female 4/7 4/3 7/3 2/2
Fig. 1 Reduced P2RY12 expression and nucleus translocation in microglia/macrophages correlated with glioma progression. a: Analysis of GEO
databases reveals decrease of P2RY12 mRNA expression with progression of glioma. Results are shown in the median values of P2RY12 mRNA
levels. ** P< 0.01; ***P< 0.005. A II: Astrocytoma WHO grade II, AA: Anaplastic Astrocytoma (WHO grade III), GBM: Glioblastoma. b: Immunohistochemical
staining for P2RY12 in normal brain and different grades of glioma. Representative pictures were selected from each group. Cells with the P2RY12 signal
localized mainly in the cytoplasm display the classic ramified microglial morphology in autopsy brain, A II and AA. Cells with nuclear location of P2RY12 are
mainly observed in GBM samples (scale bar: 100 μm). c: Quantification of percentages of P2RY12 positive areas per image field in autopsy brain, A II and
GBM. Mean values of each group are indicated. * P < 0.05, ** P < 0.01 ****P < 0.001. d: Confocal images showing CD68 and P2RY12
staining in tissue samples of liver and kidney (scale bar: 50 μm). e: Confocal images showing the spatial relation between CD68 and
P2RY12 positive cells in autopsy brain, A II, AA and GBM (scale bar: 50 μm). f: Confocal images showing no overlap between GFAP
and P2RY12 staining in astrocytoma grade II (scale bar: 20 μm)
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release of cytokines and proteases [24, 35, 38]. However,
the mechanism of microglial activation and the contribu-
tion of microglia to tumor progression are largely un-
known. In order to obtain insight in the specific action of
residential microglial cells in gliomas, proper discrimin-
ation of these cells from TAMs is necessary. So far, specific
markers for residential microglial cells that delineate these
cells from other recruited cells of monocyte lineage, are
lacking. As a matter of fact, TAMs share many markers
with microglial cells. The microglial marker Iba-1 is co-
expressed with CD45 and is therefore, not discriminative
between residential microglia and monocytic cells that
migrated into the brain [13]. In the brains of patients who
suffered from Alzheimer disease (AD) the markers CD45
and Iba-1 were used in combination with P2RY12 to
separate macrophages from microglia [13]. Considering
the growing interest in understanding the role of micro-
glial cells in gliomas, specific markers for the identification
of resident microglia in the context of primary brain
tumors are urgently needed.
Recently, the Purinergic Receptor P2Y12 (P2RY12) was
proposed as a specific marker for healthy rodent CNS
microglial cells, discriminating these cells from other types
of tissue resident macrophages or blood-derived mono-
cytes [5]. P2RY12 was claimed as a specific marker for
microglial cells in human brains [1, 6, 34]. P2RY12
belongs to the family of P2 purinergic receptors, consist-
ing of seven transmembrane G protein coupled receptors
(GPCRs) that contribute to ATP-and ADP-mediated cell
migration in vitro [7]. P2RY12 is expressed in activated
platelets and notoriously, in microglial cells [20]. P2RY12
deficiency in P2RY12 knockdown mice significantly com-
promised microglial chemotaxis and extension of micro-
glial foot processes in response to CNS injury [12, 29]. In
this study, we scrutinized P2RY12 as a marker for micro-
glial cells in glial tumors. We also investigated the relation
between the expression of P2RY12 and that of pro- or
anti-inflammatory markers; the expression sites in the
microglial cells and the relation with tumor progression.
Material and methods
Patient samples
All patient samples were obtained from the Archives
of the Department of Pathology, Erasmus Medical
Center, Rotterdam, with approval of medical ethical
committee of the Erasmus Medical Center. Twenty-
eight glioma samples (11 astrocytomas WHO grade II
(A II), 7 anaplastic astrocytomas (WHO grade III; AA)
and 10 glioblastomas (GBMs) were collected and all
diagnoses were confirmed by a certified pathologist
(JMK). The mean ages ± standard deviations and the
male/female ratio are summarized in (Table 1). Four
autopsy brains of patients who did not have brain
tumors were used as a control. Post-mortem times of
the control cases were 8 h or less.
Immunostaining
Adjacent sections of 5 μm thickness from Formalin
Fixed Paraffin Embedded (FFPE) samples were used for
immunohistochemical analysis. The sections were incu-
bated with antibodies against P2RY12 (1:100; Sigma,
Sweden); CD68 (1:800; Dako, Denmark) GFAP (1:200;
Dako, Denmark); CD45 (1:100; Dako, Denmark) and
CD163 (1:400; Abd Serotec, USA). The staining proced-
ure and scanning of the stained sections were performed
according to the protocol described previously [40]. For
double labeling, Alexa Fluor 488 and 555-conjugated
secondary antibodies (1:200, Thermo Fisher Scientific,
The Netherlands) were used for detection. For triple
staining, Goat anti-Mouse F(ab)2 fragment (Jackson
ImmunoResearch, WestGrove, PA, USA) was used to
block background epitopes and Alexa Fluor 647-
conjugated secondary antibody (Thermo Fisher Scientific,
The Netherlands) was used for detection. The fluorescent
labeled samples were analyzed by using the confocal
microscope LSM 700 (Zeiss, The Netherlands). Signal
positive areas and staining intensity were quantified using
the Image J program to five high power field (40x) areas of
each immunostained slide.
Public database
The transcription level of P2RY12 was assessed in human
gliomas of various WHO grades, using 2 different datasets
derived from the public NCBI GEO database (GDS 4467
Gene ID 64805 and GDS1816 Gene ID 64805). In
addition, transcriptional data of P2ry12 in a murine
glioma model were obtained from the GEO database
(GSE 86573) [3].
(See figure on previous page.)
Fig. 2 Cells in high grade glioma expressing P2RY12 in the nuclei are not recruited cells of myeloid origin, but resident microglia. a: Confocal
images showing P2RY12 and CD45 signals in A II, AA and GBM. No overlap between these two markers was observed in any of the gliomas
(scale bar: 50 μm). b: Confocal images showing CD68 and CD45 signals in AA (scale bars: left image; 50 μm, right panel; 20 μm). c: Confocal
images of triple staining for CD68, P2RY12 and CD45 in AA. Left image: Merged overview of triple staining (scale bar: 50 μm). Right image:
Merged high magnification of a P2RY12 positive cell (scale bar: 10 μm). d: Panel of single channel images of a P2RY12 positive cell in AA (scale
bar: 10 μm). e: Confocal images showing CD68 and CD45 staining in GBM (scale bar: left image; 50 μm, right panel; 20 μm). f: Confocal images
showing triple staining for CD68, P2RY12 and CD45 in GBM. Left panel: Merged overview of triple staining (scale bar: 50 μm). Right panel: Merged
higher magnification view of P2RY12 positive cells (scale bar: 10 μm). g: Panel of high magnification single channel images of P2RY12 positive
cells in GBM (scale bar: 10 μm)
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RNA-sequencing data of P2RY12 combined with clinical
data were obtained from two TCGA glioblastoma data-
bases (Provisional: 166 GBM patients [4]. In addition,
information on IDH1 mutation as well as MGMT methy-
lation status were also obtained from the TCGA GBM
database (Cell, 2013). The R program and CGDS-R pack-
age provided by the cBioPortal for cancer genomics from
Memorial Sloan-Kettering Cancer Center was used to
download and process data.
To study the relation between P2RY12 mRNA expres-
sion levels and markers for microglia identification, a
mutual exclusivity analysis was performed as described
previously [8, 9]. The GBM TCGA dataset (GBM,
provisional) and a low-grade glioma TCGA dataset were
selected for analysis using the cBioPortal websource
(Additional file 1: Table S1). High P2RY12 expression
was defined by a Z score ≥ 2. Z score = (individual
P2RY12 value – mean P2RY12 value) / std. dev. of the
whole sample set. A log Odd Ratio (OR) >0 indicates a
trend of co-occurrence in expression of P2RY12 with
the listed genes and log (OR) <0 indicates a trend of mu-
tual exclusivity in expression pattern.
Statistics
The results of immunostaining and the data from public
database were analyzed by the Mann-Whitney U test (P <
0.05 was considered significant). Survival analysis was per-
formed using the Log-rank test (P < 0.05 was considered
significant). All data and graphs were analyzed and made
by using Graph pad Prism 5.0.
Results
Reduction of membrane P2RY12 signal correlates with
glioma grade
The analysis of the public databases revealed that P2RY12
is mainly expressed in A II, while less in AA and GBM
(Fig. 1a). The results of immunostaining for P2RY12 are
shown in Fig. 1b. P2RY12 positive cells in autopsy brains
and A II presented the typical ramified morphology with
extended processes. In contrast, in AA a mixture of both
ramified and amoeboid P2RY12 positive cells were
noticed. In the GBMs the P2RY12 staining was less on the
cell membranes while the signal was mainly visible in the
nuclei (P2RY12nuclei+). Quantitative analysis of the per-
centage of P2RY12 positive areas per image view revealed
a significant smaller number of P2RY12 positive cells in
the AA and GBM as compared to A II (Fig. 1b, c). Double
staining of P2RY12 with the pan- macrophage marker
CD68 revealed a large population of CD68 negative,
P2RY12 positive cells (CD68- P2RY12+) distinct from
TAMs (CD68+ P2RY12-) in all glioma samples (Fig. 1e).
The population of P2RY12+ cells did not overlap with the
population of GFAP positive tumor cells or reactive astro-
cytes (Fig. 1f). In autopsy brain, A II and AA, the CD68+
TAMs generally had round cell bodies and were located
around the blood vessels. In GBM, CD68+ TAMs were
not only located around the blood vessels (Fig. 1e, white
arrows), but were spatially mixed with the P2RY12nuclei+
cells.
P2RY12nuclei+ cells are not of myeloid origin, but
represent resident microglia
Higher numbers of CD45 positive cells were observed in
AA and GBM than in A II. The CD45+ cells were mostly
present around the blood vessels (Fig. 2a, A II versus AA
versus GBM). Double staining for CD45 and P2RY12 did
not reveal double-stained cells, indicating that the P2RY12
positive cells are not derived frommyeloid lineage (Fig. 2a).
CD45 positive cells were observed in higher graded
tumors, prominently around blood vessels (Fig. 2a, A II
versus AA versus GBM). To further evaluate the identity
of CD68+P2RY12nuclei+ cells double immunostaining for
CD45 and CD68 (Fig. 2b and e) and triple immunostaining
for CD68, CD45 and P2RY12 was carried out. Two large
cell populations were observed, namely CD68+CD45
+P2RY12- and CD68+CD45-P2RY12nuclei+ cells, the former
to be interpreted as monocytes/macrophages, and the latter
as the resident microglial population (Fig. 2c, d, f, g).
In the GEO dataset GSE 86573 generated from a murine
glioma model the expression of P2ry12 by microglia (MG)
was significantly higher than that by bone marrow- de-
rived macrophages (BMDM) (Additional file 2: Figure S1).
Cytoplasmic or nuclear distribution of P2RY12 in
microglia relates to the functional marker profiles
The results of immunostaining for the M2 markers
CD163, CD204 and P2RY12 showed that cytoplasmic
P2RY12 expression did not overlap with CD163 and
CD204 positivity (Fig. 3a1-3, d1-3). In contrast, cells
with nuclear located P2RY12 showed distinct overlap
with CD163 and CD204 (Fig. 3c1-3, f1-3). Confocal
analysis revealed that cells with a low CD163 signal
show ramified cell processes and higher P2RY12
signals. Cells with a high CD163 signal are either
(See figure on previous page.)
Fig. 3 Cytoplasmatic and nuclear distribution of P2RY12 in microglia is correlated with M2-like activation in high grade glioma. a1-a3: Co-expression of
cytoplasmic P2RY12 with CD163 and CD204 in AA (scale bar: 200 μm). b1-b3: Overview of AA tissue samples (scale bar: 10 mm). c1-c3: Co-expression of
nuclear P2RY12 with CD163 and CD204 in AA (scale bar: 200 μm). d1-d3: Co-expression of cytoplasmic P2RY12 with CD163 and CD204 in GBM (scale bar:
200 μm). e1-e3: Overview of GBM tissue samples (scale bar: 10 mm). f1-f3: Co-expression of nuclear P2RY12 with CD163 and CD204 in
GBM (scale bar: 200 μm)
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negative for P2RY12, or display nuclear localization of
P2RY12 (Fig. 4a and b, cyan and white arrows). Triple
labeling for CD45, CD163 and P2RY12 differentiated
between two cell populations: CD163+ P2RY12nuclei+
cells devoid of CD45 signals and CD163+ CD45+
P2RY12+ cells (Fig. 4c and d).
Fig. 4 Confocal analysis of co-localization of P2RY12, CD163 and CD45 in GBM. a: Upper row: overview of immunostaining for P2RY12 and CD163
in a representative GBM. White arrows indicate nuclear P2RY12 signal in cells with high CD163 signal; Cyan arrows indicate cytoplasmic P2RY12
signal in cells with low CD163 signal (scale bar:100 μm). Lower row: selected view of P2RY12 and CD163 staining in glioblastoma. White arrows
indicate cells with weak P2RY12 and high CD163 signal (scale bar: 50 μm). Inserts: details of cells with low CD163 and strong cytoplasmic P2RY12
signals, and cells with strong CD163 and weak P2RY12 signals. b: Overview with two inserts. Upper panel: area with cells with nuclear P2RY12
signal with strong CD163 expression (scale bar: 50 μm). Lower panel: area with cytoplasmic P2RY12 signals and weak CD163 expression (scale bar:
50 μm). White arrows: nuclear P2RY12 expression with strong CD163 signals. c: Overview: triple staining for CD163, P2RY12 and CD45 in GBM
(scale bar: 50 μm). Inserts (scale bar: 20 μm): Cells with high CD163 and nuclear P2RY12 signals did not overlap with CD45. d: Confocal images
showing triple staining for CD163, P2RY12 and CD45 in GBM (scale bar: 20 μm). Cells with high CD163 and nuclear P2RY12 signal did not overlap
with CD45
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High expression levels of P2RY12 are associated with
favorable clinical outcomes
P2RY12 RNA expression data was obtained from two
TCGA glioma databases. From the glioma database [4], 151
patients were collected for analysis (Table 2). Twenty-one
tumors with at least 1-fold increase of P2RY12 expression
were defined as the “P2RY12 high” group, while the tumors
expressing P2RY12 al lower levels than 1-fold increase were
defined as the “P2RY12-low” group. Patients with tumors
of the P2RY12-high group had longer overall survival
times (P = 0.03), but not a longer disease free survival
than those in the P2RY12-low group (Fig. 5a). In the
glioma provisional database from TCGA the P2RY12-
high group showed a trend of longer disease free sur-
vival (P = 0.0608) as well as a significant increase in
overall survival time (P = 0.0446) (Additional file 3:
Figure S2a and b, upper and lower graph). Univariate
analysis by the Log-rank test revealed that patients in
the P2RY12-high group have lower hazard ratios for
disease recurrence (HR = 0.445, P = 0.0187) than pa-
tients in the P2RY12 low group. Similarly, the P2RY12-
high group has a lower hazard ratio for overall survival
versus the P2RY12-low group (HR = 0.4598, P = 0.04)
(Additional file 3: Figure S2c). The data show that
P2RY12 up-regulation positively correlates with prognosis
and overall survival of GBM patients. The expressional
levels of P2RY12 are significantly higher in gliomas with
the IDH1 (R132H) mutation as compared to the IDH wt
gliomas (Additional file 4: Figure S3a). There is, however,
no effect of P2RY12 expression on overall survival when
the population was stratified for IDH1 mutation status
(Additional file 4: Figures S3b and c). There were no
expressional differences of P2RY12 between gliomas with
or without MGMT promoter methylation (Additional file
5: Figure S4a). The expression of P2RY12 did not affect
the overall survival of the patients when stratified for
MGMT promoter methylation status (Additional file 5:
Figures S4b and c).
P2RY12 expression correlates with microglia/macrophage
function
P2RY12 had a significant likelihood for co-occurrence
with the microglia markers Iba-1 and CX3CR1 in
GBM, and CX3CR1, CD11b in low grade glioma. Like-
wise, IRF8, a transcription factor for the function and
development of microglia cells [14, 15] is expressed
simultaneous with P2RY12 in both GBM and low
grade gliomas. Due to the limited number of samples
in the high P2RY12 expression group, the p-values of
associations with log(OR) < -3 remain non-significant,
despite a high probability and tendency for mutual
exclusion.
The associations between P2RY12 and other markers
are listed in the Additional file 1: Table S1. Genes posi-
tively (Spearman r ≥0.5) or negatively (Spearman r ≤ -
0.3) correlated with P2RY12 from the two TCGA GBM
database were selected for pathway enrichment analysis
(Fig. 5b, d). Pathway analysis from Gene Ontology based
on 222 P2RY12 positively correlating genes included the
regulation of immune response including defense re-
sponse, leukocyte activation, T cell activation (Fig. 5c).
Pathway analysis on 58 P2RY12 negatively correlating
genes mainly included cell cycle regulation and cell pro-
liferation (Fig. 5e). The findings indicate that P2RY12
expression is positively correlated with markers com-
monly used for microglia in the CNS and positive im-
mune response, but is inversely associated with markers
for peripheral recruited macrophages, M2-like micro-
glia/macrophage activation and cell proliferation.
Table 2 Summary of patients’ information from TCGA GBM
database
TCGA GBM Database n = 151
P2RY12 High
(n = 21)
Low
(n = 130)
mRNA level
± S.D
(RNA Seq V2 RSEM) 3263 ± 722.6 499.5 ± 580.1
Age (year)
± S.D
55.1 ± 15.1 61.5 ± 12.4
Gender Male 17(21) 79(130)
Female 4(21) 51(130)
IDH1
mutation
WT 17(21) 127(130)
Mutant 4(21) 3(130)
Subtype Neural 7(21) 19(130)
Pro-Neural 1(21) 27(130)
Classical 4(21) 35(130)
Mesenchymal 5(21) 44(130)
G-CIMP 4(21) 4(130)
N/A 0 1(130)
Therapy TMZ Chemoradiation,
TMZ Chemo
9(21) 55(130)
Standard Radiation, TMZ
Chemo
3(21) 21(130)
Nonstandard Radiation,
TMZ Chemo
2(21) 11(130)
Standard Radiation, Alkylating
Chemo
1(21)
Unspecified Radiation 6(21) 17(130)
Alkylating Chemo 1(130)
Standard Radiation 12(130)
Standard Radiation, Alkylating
Chemo
3(130)
TMZ Chemo 1(130)
Nonstandard Radiation 4(130)
Unspecified Therapy 5(130)
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Discussion
In the present study, we found that resident microglial
cells in gliomas specifically express P2RY12 and that the
expression distinguishes microglia from other monocytes
and macrophages. This finding in human gliomas cor-
roborates the data we generated from the murine gli-
omas represented in the GEO database. The analysis of
the public glioma datasets and the multi-labeling experi-
ments of the glioma biopsy specimens confirmed that
P2RY12 mRNA and protein expression is confined to
resident microglial cells. In addition, P2RY12 expression
is associated with tumor grade: the expression is less in
AA and GBM, as compared to A II. However, the ex-
pression of P2RY12 is not an independent prognostica-
tor in gliomas; when strong prognostic factors as IDH
mutational status or methylation status of MGMT are
taken into consideration, no additional effects of the ex-
pression are found. The expression of P2RY12 appeared
Fig. 5 Analysis of TCGA datasets: High expression levels of P2RY12 in GBM patients predict a favorable outcome. a: Kaplan-Meier curves showing disease
free survival and overall survival curves of patients with different P2RY12 expression levels. b: Overlap of the genes found in the two datasets that positively
correlate with P2RY12 expression. c: Top 20 most significant biological processes resulting from functional annotation of the 222 overlapping genes. The
GO terms are shown on the y-axis. The numbers of input genes per GO term are indicated on the x-axis. d: Overlap of the genes found in the two datasets
that negatively correlate with P2RY12 expression. e: Top 20 most significant biological processes resulting from functional annotation of the 58 overlapping
genes. The GO terms are shown on the y-axis. The numbers of input genes per GO term are indicated on the x-axis
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to be higher in the IDH mutated tumors, which is in line
with the association of IDH mutation and better progno-
sis on the one hand, and the pro-inflammatory status on
the other. Remarkably, with increasing malignancy grade
there is a shift from cytoplasmic to nuclear expression,
and in the high-grade tumors the nuclear expression of
P2RY12 coincides with that of the M2 markers CD163
and CD204 (Fig. 1a and c, Fig. 4). We also observed that
in the high-grade gliomas the P2RY12 positive microglial
cells have taken an amoeboid phenotype (Fig. 1b).
Upon pathologic stimuli, resting microglia adopt a highly
dynamic phenotype referred to as “ramified microglia”, with
an extensive motile set of foot processes that continuously
survey the local environment to recognize and eliminate
pathogens [6]. Loss of microglial expression of P2RY12 in
knockout mice resulted in impaired polarization, migration
and extension of microglial processes towards extracellular
nucleotides released from damaged cells, indicating that
P2RY12 is required to guide microglial chemotaxis [12].
Further studies revealed that a raise of local extracellular
ATP/ADP levels at the site of CNS injury activates Gi/o-
coupled P2RY12, followed by PI3K and PLC signaling-
mediated migration of microglial cells towards the chemo-
tactic source [7]. Exogenous stimuli like lipopolysaccharides
(LPS) can cause a dramatic reduction of the P2RY12
expression in microglia cells in vitro accompanied by the
retraction of microglial processes and metamorphosis into
an amoeboid shape [12]. These phenomena indicate a func-
tion of P2RY12 in the activation of immune regulation
during inflammation.
The environmental changes taking place under various
pathological conditions cause ATP/ADP leaks that are
noticed by the P2RY12 receptors of microglia and lead to
changes affecting the cell processes and motility of the
cells [16]. High concentrations of purinergic nucleotides
and nucleosides such as adenosine and ATP were shown
to work in synergy with LPS activation of microglial cells,
promoting chemo repulsion away from the ATP source, a
process that is associated with increased local adenosine
A2A receptor signaling [16, 30]. The expression of the
adenosine A2A receptor increases significantly in response
to LPS, while P2RY12 expression decreased by LPS, indi-
cating that the shift from a ramified towards an amoeboid
phenotype depends on the balance between P2RY12 and
A2A receptor signaling, respectively [16]. More studies
are required to elucidate the exact regulatory mechanism
of microglia immune-activation by these two significant
signaling pathways.
In this study we observed nuclear localization of P2RY12
in microglial cells in the high-grade tumors, while in the
lower graded astrocytomas P2RY12 was expressed in the
cytoplasm. G protein-coupled receptors (GPCRs), such as
P2RY12 and its family members are considered as cell
surface bound mediators of intracellular signaling. From in
vitro and in vivo studies, it is known that some receptors
have a nuclear localization. These receptors include the
receptors for apelin, angiotensin II AT1, parathyroid
hormone, glutamate mGluR5, endothelin ETA and ETB,
and the prostaglandins EP1, EP3, and EP4 [21]. The mech-
anism and functional implications of nuclear translocation
remains obscure. It has been suggested that nuclear import
is programmed by the DNA sequence of the receptors. Nu-
clear GPCRs complex proteins such as heterotrimeric G
proteins, phospholipase A2, and phospholipase C seem to
remain active in intracellular signaling, similar to the activa-
tion of nuclear endothelin and prostaglandin receptors that
were proven to increase nuclear Ca2+concentrations [21].
However, the functional implications of nuclear localization
of the P2RY12 receptor and its association with advanced
tumor grade needs to be further unraveled.
Conclusion
The expression site of P2RY12 matches astrocytoma grade,
and also reflects the activation status of microglia cells in
the tumors. Because of its association with the stage of
immune response, P2RY12 may become an interesting
drug target for future immune-modulation based therapy
for the patients suffering from these tumors.
Additional files
Additional file 1: Table S1. Summary of mutual exclusivity analysis from
two TCGA glioma database. TCGA GBM provisional database and low grade
glioma database were analyzed from cBioPortal. P2RY12 upregulation was
defined by Z score. Z score = (Individual P2RY12 value-mean value)/Standard
deviation of whole sample set. (DOC 62 kb)
Additional file 2: Figure S1. Higher expression of P2ry12 in microglia
than bone marrow derived macrophages in a mouse glioma model. It
appears from the GEO dataset (GSE 86573) that P2ry12 mRNA is expressed
by microglia (MG) and not by bone marrow-derived macrophages (BMDM)
(Results are shown as Mean ± S.E.M representing the level of P2ry12 mRNA);
** P < 0.01. (TIF 2273 kb)
Additional file 3: Figure S2. High expression of P2RY12 in GBM
patients is predictive of favorable outcome. a: Overview of P2RY12
expression levels of 166 GBM samples from the TCGA GBM
provisional database. b: (upper panel) Kaplan-Meier curves showing
significantly different disease free survival between patients with
high, versus low- or intermediate P2RY12 expression levels. (lower
panel) Kaplan-Meier curves showing significantly different overall
survival between patients with high, versus low or intermediate
P2RY12 expression levels. c: Graph showing hazard ratios (HR) with
95% confidential interval (CI) of disease free survival and overall
survival for the distinct P2RY12 expression levels. (TIF 72698 kb)
Additional file 4: Figure S3. Expression of P2RY12 does not influence
overall survival in groups stratified for IDH1 mutation status (TCGA
database). a. Increased P2RY12 mRNA expression in gliomas with
IDH1 (R132H) mutation. Results are shown for the median values of
P2RY12 mRNA levels; * P < 0.05; WT: IDH Wild type. b. Kaplan-Meier
curves showing no effect of P2RY12 expression level on overall survival within
the group of patients with IDH1 wild type gliomas (P> 0.1). c. Kaplan-Meier
curves showing no effect of P2RY12 expression level on overall survival within
the group of patients with IDH1 mutant (R132H) gliomas (P> 0.1).
(TIF 10499 kb)
Zhu et al. Acta Neuropathologica Communications  (2017) 5:4 Page 10 of 12
Additional file 5: Figure S4. P2RY12 does influence overall survival in
gliomas stratified for MGMT promoter methylation status (TCGA database).
a. P2RY12 mRNA expression levels in gliomas with and without MGMT
promoter methylation (median values of P2RY12 mRNA levels are shown).
b. Kaplan-Meier curves showing no influence of P2RY12 expression level on
overall survival within the glioma group with methylated MGMT promoter.
c. Kaplan-Meier curves showing no influence of P2RY12 expression level on
overall survival within the glioma group with unmethylated MGMT
promoter. (TIF 14397 kb)
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